DE69825906D1 - Verwendung von angiostatische steroide in photodynamischer therapie - Google Patents

Verwendung von angiostatische steroide in photodynamischer therapie

Info

Publication number
DE69825906D1
DE69825906D1 DE69825906T DE69825906T DE69825906D1 DE 69825906 D1 DE69825906 D1 DE 69825906D1 DE 69825906 T DE69825906 T DE 69825906T DE 69825906 T DE69825906 T DE 69825906T DE 69825906 D1 DE69825906 D1 DE 69825906D1
Authority
DE
Germany
Prior art keywords
photodynamic therapy
angiostatic steroids
angiostatic
steroids
steriod
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69825906T
Other languages
English (en)
Other versions
DE69825906T2 (de
Inventor
Abbot F Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Research LLC
Original Assignee
Alcon Manufacturing Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Manufacturing Ltd filed Critical Alcon Manufacturing Ltd
Publication of DE69825906D1 publication Critical patent/DE69825906D1/de
Application granted granted Critical
Publication of DE69825906T2 publication Critical patent/DE69825906T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0027—Azides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
DE69825906T 1997-07-16 1998-06-18 Verwendung von angiostatische steroide in photodynamischer therapie Expired - Fee Related DE69825906T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US895184 1997-07-16
US08/895,184 US5770592A (en) 1991-11-22 1997-07-16 Prevention and treatment of ocular neovascularization using angiostatic steroids
PCT/US1998/012711 WO1999003503A1 (en) 1997-07-16 1998-06-18 The use of angiostatic steroids in photodynamic therapy

Publications (2)

Publication Number Publication Date
DE69825906D1 true DE69825906D1 (de) 2004-09-30
DE69825906T2 DE69825906T2 (de) 2005-09-01

Family

ID=25404127

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69825906T Expired - Fee Related DE69825906T2 (de) 1997-07-16 1998-06-18 Verwendung von angiostatische steroide in photodynamischer therapie

Country Status (13)

Country Link
US (2) US5770592A (de)
EP (1) EP1003553B1 (de)
JP (1) JP2001510170A (de)
AT (1) ATE274356T1 (de)
AU (1) AU734195B2 (de)
BR (1) BR9811012A (de)
CA (1) CA2296558A1 (de)
DE (1) DE69825906T2 (de)
DK (1) DK1003553T3 (de)
ES (1) ES2224412T3 (de)
HK (1) HK1028952A1 (de)
PT (1) PT1003553E (de)
WO (1) WO1999003503A1 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2358296A1 (en) * 1999-01-05 2000-07-13 Anthony P. Adamis Targeted transscleral controlled release drug delivery to the retina and choroid
CA2358662A1 (en) * 1999-01-15 2000-07-20 James Chen Therapeutic compositions for metabolic bone disorders or bone metastases
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
AU2412800A (en) 1999-01-15 2000-08-01 Light Sciences Corporation Noninvasive vascular therapy
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
PT1473003E (pt) 1999-10-21 2008-12-26 Alcon Inc Dispositivo para administração de fármacos
WO2001028473A1 (en) 1999-10-21 2001-04-26 Alcon Universal Ltd. Sub-tenon drug delivery
US7943162B2 (en) * 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
US7678836B2 (en) * 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
WO2001058240A2 (en) * 2000-02-10 2001-08-16 Massachusetts Eye And Ear Infirmary Photodynamic therapy for treating conditions of the eye
CZ20023174A3 (cs) * 2000-03-24 2003-01-15 Novartis Ag Farmaceutické prostředky obsahující antiangiogenní léčivo a fotosenzitivní činidlo
EP1570859A3 (de) * 2000-03-24 2008-04-02 Novartis AG Verbesserte Behandlung von Neovaskularisation
US9603741B2 (en) 2000-05-19 2017-03-28 Michael S. Berlin Delivery system and method of use for the eye
DE60131273T2 (de) * 2000-05-19 2008-08-28 Michael S. Beverly Hills Berlin Laserapplikationssystem und methode zur verwendung im auge
US8679089B2 (en) 2001-05-21 2014-03-25 Michael S. Berlin Glaucoma surgery methods and systems
EP1387671A1 (de) 2001-05-03 2004-02-11 MASSACHUSETTS EYE & EAR INFIRMARY Implantierbare arzneistoffverabreichungsvorrichtung und verwendung derselben
CN100349562C (zh) * 2001-07-23 2007-11-21 爱尔康公司 眼部药物输送装置
AU2002319596B2 (en) 2001-07-23 2006-04-27 Alcon, Inc. Ophthalmic drug delivery device
AU2002331916B2 (en) * 2001-10-03 2008-07-24 Merck Sharp & Dohme Corp. Androstane 17-beta-carboxamides as androgen receptor modulators
TWI260327B (en) * 2001-11-09 2006-08-21 Osi Eyetech Inc Pharmaceutical compositions for treating ocular neovascular diseases
US6723750B2 (en) 2002-03-15 2004-04-20 Allergan, Inc. Photodynamic therapy for pre-melanomas
AU2003217531A1 (en) * 2002-05-02 2003-11-17 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
CA2492964C (en) 2002-07-24 2012-07-17 Qlt Inc. Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
US6806364B2 (en) * 2002-07-29 2004-10-19 Ast Products, Inc. Ophthalmic compositions
CA2494449A1 (en) * 2002-07-29 2004-02-05 Ast Products, Inc. Ophtalmic compositions
US6828356B2 (en) * 2002-07-29 2004-12-07 Ast Products, Inc. Preparation of ophthalmic compositions
WO2004012742A1 (en) * 2002-08-05 2004-02-12 Alcon, Inc. Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
DE10238310A1 (de) * 2002-08-21 2004-03-04 Erich Jaeger Gmbh Elektrodenanordnung
CA2500877A1 (en) * 2002-10-03 2004-04-15 Light Sciences Corporation Excitation of photoreactive compounds in eye tissue
WO2004073551A2 (en) * 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
CN1750828A (zh) * 2003-02-20 2006-03-22 爱尔康公司 类固醇治疗眼病患者的用途
US20040167109A1 (en) * 2003-02-20 2004-08-26 Bingaman David P Formulations of glucocorticoids to treat pathologic ocular angiogenesis
RU2006101150A (ru) * 2003-06-13 2006-06-10 Алькон, Инк. (Ch) Композиции нестероидных противовоспалительных средств для лечения патологического ангиогенеза глаз
US20040258769A1 (en) * 2003-06-20 2004-12-23 Barker Ronnie C. Use of ocular vitamins in conjunction with other treatment methods for AMD
KR20060082792A (ko) * 2003-07-10 2006-07-19 알콘, 인코퍼레이티드 안과용 약물 전달 장치
US7585517B2 (en) * 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
MXPA06003185A (es) * 2003-09-23 2006-06-23 Alcon Inc Formulaciones de acetonuro de triamcinolona y de acetato de anecotarve para inyeccion.
WO2005072744A1 (ja) * 2004-02-02 2005-08-11 Yuichi Kaji 硝子体の可視化剤
JP2007523202A (ja) * 2004-02-24 2007-08-16 ビオアクソン・テラプティーク・インコーポレーテッド ４置換ピペリジン誘導体
US20050239760A1 (en) * 2004-04-23 2005-10-27 Alcon, Inc. Angiostatic agents and methods and compositions for controlling ocular hypertension
US20060116404A1 (en) * 2004-09-24 2006-06-01 Gary Robinson CAI-based systems and methods for the localized treatment of ocular and other diseases
US20160106717A1 (en) 2004-09-24 2016-04-21 Gen Pharma Holdings LLC Cai-based systems and methods for the localized treatment of uveitis
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
BRPI0607606B1 (pt) * 2005-02-09 2021-06-22 Santen Pharmaceutical, Co., Ltd. Formulação líquida
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
WO2006126095A2 (en) 2005-05-25 2006-11-30 Chemisches Institut Schaefer Ag Biocompatible polymers and co-polymers comprising amino acids in the side chain
ES2447025T3 (es) * 2005-07-12 2014-03-11 Ampio Pharmaceuticals, Inc. Métodos y productos para el tratamiento de enfermedades
AU2006272497B2 (en) 2005-07-27 2012-07-19 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
US7261529B2 (en) * 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US7758778B2 (en) * 2005-09-07 2010-07-20 Southwest Research Institute Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US9693967B2 (en) * 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
PL2960253T3 (pl) 2005-09-07 2018-11-30 Amgen Fremont Inc. Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do receptora aktywiny-1
WO2007047626A1 (en) * 2005-10-14 2007-04-26 Alcon, Inc. Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis
BRPI0617414A2 (pt) * 2005-10-14 2011-07-26 Alcon Inc mÉtodo para tratamento de formas primÁrias e secundÁrias de glaucoma
US20080125406A1 (en) * 2005-10-14 2008-05-29 Robin Alan L Method for Treating Primary and Secondary Forms of Glaucoma
KR20080065704A (ko) 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 의학적 이상의 치료 방법들, 조성물들, 및 키트들
SI1968594T1 (sl) 2005-11-29 2011-01-31 Glaxosmithkline Llc Tretma okularnih neovaskularnih motenj, kot makularne degeneracije, angiodnih prog. uveitisa in makularnega edema
EP2001438A2 (de) 2006-02-09 2008-12-17 Macusight, Inc. Stabile formulierungen sowie verfahren zu ihrer herstellung und verwendung
JP5506378B2 (ja) 2006-03-23 2014-05-28 参天製薬株式会社 血管透過性に関連する疾患または病気のための製剤および方法
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US20170360609A9 (en) 2007-09-24 2017-12-21 Ivantis, Inc. Methods and devices for increasing aqueous humor outflow
US20090181933A1 (en) * 2008-01-11 2009-07-16 Bingaman David P Use of steroids to treat persons suffering from ocular disorders
EP2259833A1 (de) 2008-03-05 2010-12-15 Ivantis, INC. Verfahren und vorrichtung zur behandlung von glaukom
CN103739647B (zh) 2008-05-28 2017-06-09 雷沃根生物医药有限公司 用于治疗疾病的NF‑κB的非激素甾体调节剂
US8632511B2 (en) 2009-05-06 2014-01-21 Alcon Research, Ltd. Multiple thermal sensors in a multiple processor environment for temperature control in a drug delivery device
IN2012DN00352A (de) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
EP2445350A4 (de) * 2009-06-22 2012-12-26 Dmi Acquisition Corp Verfahren und produkte zur behandlung von erkrankungen
PL2554172T3 (pl) 2009-06-22 2015-03-31 Ampio Pharmaceuticals Inc Sposób leczenia chorób
CA2766192C (en) 2009-07-09 2017-10-24 Ivantis, Inc. Ocular implants for residing partially in schlemm's canal
WO2011006078A1 (en) 2009-07-09 2011-01-13 Ivantis, Inc. Single operator device for delivering an ocular implant
WO2011039648A1 (en) 2009-09-30 2011-04-07 Glaxo Wellcome Manufacturing Pte Ltd. Methods of administration and treatment
US8177747B2 (en) 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
EP2556083A4 (de) 2010-04-05 2013-12-04 Validus Biopharma Inc Nichthormonale steroide modulatoren von nf-kappa-b zur krankheitsbehandlung
US20120283557A1 (en) 2011-05-05 2012-11-08 Berlin Michael S Methods and Apparatuses for the Treatment of Glaucoma using visible and infrared ultrashort laser pulses
US8657776B2 (en) 2011-06-14 2014-02-25 Ivantis, Inc. Ocular implants for delivery into the eye
EP2720539B1 (de) 2011-06-14 2018-10-24 Bikam Pharmaceuticals, Inc. Opsinbindende liganden, deren zusammensetzungen und anwendungsverfahren
AU2012325341B2 (en) 2011-10-19 2017-01-05 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
EP2944628B1 (de) 2011-11-30 2017-01-04 Bikam Pharmaceuticals, Inc. Opsinbindende liganden, zusammensetzungen und verfahren zur verwendung
EP2785178B1 (de) 2011-12-01 2019-05-01 Bikam Pharmaceuticals, Inc. Opsinbindende liganden, zusammensetzungen damit und anwendungsverfahren dafür
US8663150B2 (en) 2011-12-19 2014-03-04 Ivantis, Inc. Delivering ocular implants into the eye
US9358156B2 (en) 2012-04-18 2016-06-07 Invantis, Inc. Ocular implants for delivery into an anterior chamber of the eye
WO2014085450A1 (en) 2012-11-28 2014-06-05 Ivantis, Inc. Apparatus for delivering ocular implants into an anterior chamber of the eye
AU2013361338A1 (en) 2012-12-19 2015-08-06 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
US10709547B2 (en) 2014-07-14 2020-07-14 Ivantis, Inc. Ocular implant delivery system and method
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10857157B2 (en) 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10149856B2 (en) 2015-01-26 2018-12-11 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
WO2017004205A1 (en) 2015-06-29 2017-01-05 Reveragen Biopharma, Inc. NON-HORMONAL STEROID MODULATORS OF NF-κB FOR TREATMENT OF DISEASE
AU2016307951B2 (en) 2015-08-14 2021-04-01 Alcon Inc. Ocular implant with pressure sensor and delivery system
WO2017106517A1 (en) 2015-12-15 2017-06-22 Ivantis, Inc. Ocular implant and delivery system
US11198680B2 (en) 2016-12-21 2021-12-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10537567B2 (en) 2017-07-11 2020-01-21 BioAxone BioSciences, Inc. Kinase inhibitors for treatment of disease
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
AU2022205382A1 (en) 2021-01-11 2023-06-22 Alcon Inc. Systems and methods for viscoelastic delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
US5371078A (en) 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
AU657690B2 (en) * 1990-06-11 1995-03-23 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis
CA2536069C (en) 1994-03-14 2008-06-03 Massachusetts Eye And Ear Infirmary Use of green porphyrins in ocular diagnosis and therapy

Also Published As

Publication number Publication date
EP1003553B1 (de) 2004-08-25
US5770592A (en) 1998-06-23
ES2224412T3 (es) 2005-03-01
DE69825906T2 (de) 2005-09-01
DK1003553T3 (da) 2004-09-20
CA2296558A1 (en) 1999-01-28
ATE274356T1 (de) 2004-09-15
HK1028952A1 (en) 2001-03-16
AU734195B2 (en) 2001-06-07
BR9811012A (pt) 2000-10-17
AU8151598A (en) 1999-02-10
JP2001510170A (ja) 2001-07-31
PT1003553E (pt) 2004-10-29
US6297228B1 (en) 2001-10-02
EP1003553A1 (de) 2000-05-31
WO1999003503A1 (en) 1999-01-28

Similar Documents

Publication Publication Date Title
ATE274356T1 (de) Verwendung von angiostatische steroide in photodynamischer therapie
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
AU2592600A (en) Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
ATE324119T1 (de) Verwendung von saccharid-konjugaten
DE69434491D1 (de) Hautpflaster enthaltend testosteron und gegebenenfalls estrogen
ES2082198T3 (es) Inhibidores de esteroide-sulfatasa.
ATE424211T1 (de) Therapeutische verwendung von sapogeninen
DE60040753D1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
DE60216300D1 (de) Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
ATE247709T1 (de) 3'utr des menschliches prohibitin-gens
ATE442861T1 (de) Gegen antikörper gerichtete photodynamische therapie
TR199901003T2 (xx) Ast�m tedavisi i�in loratadin ve bir dekonjestan i�eren bile�im.
DE69705421D1 (de) 15-fluoro-prostaglandine als augendrucksenkende mittel
DE69729004D1 (de) Photodynamische therapie zur behandlung von osteosrthritis
ATE306270T1 (de) Verwendung von fulvestrant in der behandlung von resistentem brustkrebs
ATE285247T1 (de) Krebstherapie mit lymphotoxin
DE69710333D1 (de) Cyclopentan(en)säure-2-alkenyl-derivate als therapeutika in der behandlung der okulären hypertonie
DK1131073T3 (da) Anvendelse af staurosporinderivater til behandling af okulære neovaskulære sygdomme
MXPA05008396A (es) Formulaciones de glucocorticoides para tratar angiogenesis ocular patologica.
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
BR9607178A (pt) Antagonista de peptìdeo de hormÈnio estimulando alfa -melanócitos, processos para a inibição da atividade de hormÈnio estimulando alfa-melanócitos em um tecido ou célula que responde a hormÈnio estimulando alfa -melanócitos, para o clareamento da complexação de um animal e para o tratamento de melanoma maligno, composição farmacêutica, e, kit
DE60319719D1 (de) Verfahren zur voraussage der erhöhung von cholesterin während einer immunosuppresiven therapie
ATE239076T1 (de) Zielspezifische abgabe zum nukleus mittels protein h von streptococcus
DK0900085T3 (da) Behandling af overdreven aggression med olanzapin
ATE271878T1 (de) Verwendung von protein h als zytostattischer wirkstoff

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee